FFO
SION

Fortitude Family Office’s Sionna Therapeutics SION Stock Holding History

Fortitude Family Office’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660 Hold
15
– – ﹤0.01% 1903
2026
Q1 		$601 Buy
+15
New +$572 ﹤0.01% 1662

Other funds holding SION

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

Fortitude Family Office's SION Position: Q2 2026 in Review

Fortitude Family Office held its Sionna Therapeutics (SION) position steady in Q2 2026 at 15 shares worth $660. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Fortitude Family Office first reported a position in SION in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Fortitude Family Office held 15 shares of Sionna Therapeutics worth $660 as of Q2 2026.
  • Fortitude Family Office left its Sionna Therapeutics share count unchanged in Q2 2026.
  • Sionna Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1903 holding.
  • Fortitude Family Office first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.